Although DCV Direct is not being tested on any brain tumor in the current trial, these gliomas might be better suited for treatment with Direct over L for the reason you postulate.
Frankly, if Direct performs as it did pre-clinical, it seems to me that it would become part of SOC. Can you see a situation where L would be used over Direct, should Direct prove effective?
News 
Market Data 
Discover 
